Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
MBRX

MBRX - Moleculin Biotech Inc Stock Price, Fair Value and News

4.35USD+0.40 (+10.13%)Delayed

Market Summary

MBRX
USD4.35+0.40
Delayed
10.13%

MBRX Stock Price

View Fullscreen

MBRX RSI Chart

MBRX Valuation

Market Cap

10.1M

Price/Earnings (Trailing)

-0.37

EV/EBITDA

0.34

Price/Free Cashflow

-0.4

MarketCap/EBT

-0.64

MBRX Price/Sales (Trailing)

MBRX Profitability

Return on Equity

-124.26%

Return on Assets

-86.96%

Free Cashflow Yield

-247.88%

MBRX Fundamentals

MBRX Earnings

Earnings (TTM)

-26.8M

Earnings Growth (Yr)

37.21%

Earnings Growth (Qtr)

51.6%

Breaking Down MBRX Revenue

Last 7 days

24.6%

Last 30 days

0.7%

Last 90 days

-6.0%

Trailing 12 Months

504.2%

How does MBRX drawdown profile look like?

MBRX Financial Health

Current Ratio

3.51

MBRX Investor Care

Shares Dilution (1Y)

16.84%

Tracking the Latest Insider Buys and Sells of Moleculin Biotech Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 22, 2024
klemp walter v
sold (taxes)
-8,190
3.74
-2,190
ceo and president
Jun 22, 2024
klemp walter v
acquired
-
-
8,990
ceo and president
Jun 22, 2024
foster jonathan p.
sold (taxes)
-3,938
3.74
-1,053
chief financial officer
Jun 22, 2024
foster jonathan p.
acquired
-
-
4,329
chief financial officer
Jun 22, 2024
picker donald h
sold (taxes)
1,959
3.74
524
chief science officer
Jun 22, 2024
picker donald h
acquired
-
-
1,766
chief science officer
Jun 20, 2024
klemp walter v
sold (taxes)
-3,454
3.78
-914
ceo and president
Jun 20, 2024
klemp walter v
acquired
-
-
3,750
ceo and president
Jun 20, 2024
foster jonathan p.
sold (taxes)
-2,404
3.78
-636
chief financial officer
Jun 20, 2024
foster jonathan p.
acquired
-
-
2,712
chief financial officer

1–10 of 50

Which funds bought or sold MBRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 10, 2024
NBC SECURITIES, INC.
sold off
-100
-1,000
-
-%
Jul 10, 2024
CVA Family Office, LLC
unchanged
-
-81.00
120
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
sold off
-100
-2,753,250
-
-%
May 15, 2024
STATE STREET CORP
sold off
-100
-61,287
-
-%
May 15, 2024
MORGAN STANLEY
sold off
-100
-5,437
-
-%
May 15, 2024
MORGAN STANLEY
new
-
2,500
2,500
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-118
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
new
-
41.00
41.00
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
new
-
877,605
877,605
0.01%
May 15, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-6,178
-
-%

1–10 of 46

Are Funds Buying or Selling MBRX?

Are funds buying MBRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MBRX
No. of Funds

Unveiling Moleculin Biotech Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.99%
3,316,221
SC 13G
Feb 10, 2021
vanguard group inc
0.95%
591,954
SC 13G/A
Jan 20, 2021
empery asset management, lp
4.57%
2,990,053
SC 13G/A
Jan 04, 2021
sabby management, llc
4.99%
3,116,982
SC 13G/A
Nov 13, 2020
lincoln park capital fund, llc
7.52%
4,787,254
SC 13G
Feb 11, 2020
vanguard group inc
5.69%
2,602,114
SC 13G
Feb 11, 2020
empery asset management, lp
7.05%
3,750,000
SC 13G
Feb 10, 2020
cvi investments, inc.
3.8%
1,800,000
SC 13G/A
Feb 07, 2020
sabby management, llc
7.05%
3,750,000
SC 13G
Jan 08, 2020
sabby management, llc
4.99%
2,281,812
SC 13G/A

Recent SEC filings of Moleculin Biotech Inc

View All Filings
Date Filed Form Type Document
Jul 10, 2024
8-K
Current Report
Jul 05, 2024
4
Insider Trading
Jul 01, 2024
EFFECT
EFFECT
Jun 25, 2024
4
Insider Trading
Jun 25, 2024
4
Insider Trading
Jun 25, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading

Peers (Alternatives to Moleculin Biotech Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-17.79% -4.08%
-7.8
6.8
-64.45% -224.75%
33.0B
2.0B
63.81% 27.79%
-99.24
16.45
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
0.60% -0.76%
78.61
6.53
13.74% 186.89%
14.3B
3.8B
6.19% 2.76%
19.17
3.79
8.58% 129.81%
MID-CAP
5.1B
107.9M
-5.51% 56.56%
-9.28
48.09
54.84% -28.31%
4.8B
524.1M
-6.99% -54.02%
-11.5
9.15
394.93% 39.61%
3.9B
251.0M
15.74% 13.44%
-13.27
15.67
73.58% -86.73%
3.5B
240.7M
9.12% -18.47%
-7.38
12.77
-1.03% -213.92%
2.9B
813.8M
15.55% -31.16%
-1.7K
3.61
56.43% 98.83%
1.8B
996.6M
-17.40% 41.77%
-4.61
1.85
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
7.18% 31.22%
30.04
4.76
60.38% -34.49%
628.3M
881.7K
14.71% 639.50%
-18.61
481.06
-77.61% 33.36%
293.1M
4.2M
19.30% 68.30%
-2.35
70.45
-66.30% 48.24%
21.0M
2.1M
-4.31% -79.32%
-0.91
7.61
-13.45% 69.54%

Moleculin Biotech Inc News

Latest updates
StockTitan10 Jul 202402:00 pm
PR Newswire3 months ago

Moleculin Biotech Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-19.3%30,84538,21739,52347,11551,06257,42265,37273,25578,80184,09088,70293,53499,78429,03127,14431,38025,47225,23530,39831,85421,298
  Current Assets-27.8%18,95726,27327,60335,38039,28945,59653,49361,32267,26072,49777,07081,83688,01917,19815,25019,74913,78713,48418,58620,2029,613
    Cash Equivalents-28.6%16,82423,55024,57932,17237,26543,14550,39257,99966,10470,90375,17879,50686,29315,17312,79516,73411,64910,73515,40918,6958,782
  Net PPE-11.8%240272225229244275306339312338353395438483522238271316358401431
Liabilities-23.8%9,25812,1444,3856,8475,3785,2316,9556,8966,1365,0977,4438,83411,26811,27112,67715,75110,1809,66411,4239,7626,616
  Current Liabilities-20.6%5,4086,8153,8886,5545,0324,8196,3625,8594,8343,6223,6563,3504,5782,9203,4383,7393,2353,57011,1199,5916,436
Shareholder's Equity-17.2%21,58726,07335,13840,26845,68452,19158,41766,35972,66578,99381,25984,70088,51617,76014,46715,62915,29215,57118,97522,09214,682
  Retained Earnings-3.8%-136,600-131,604-121,335-115,726-109,750-101,835-95,100-86,454-79,677-72,810-69,984-65,600-61,400-56,916-54,300-50,882-40,800-39,561-35,763-31,600-30,397
  Additional Paid-In Capital0.3%158,177157,653156,446155,957155,396153,985153,450152,762152,260151,733151,175150,231149,78874,67168,64966,42856,01155,05554,67353,64345,021
Accumulated Depreciation-100.0%-896---769---638---474---284---
Shares Outstanding3.8%2,3122,2281,9871,9861,917-1,9091,9061,9051,9051,7541,677---------
Float----16,000---40,000---101,000---52,000---48,000-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-24.2%-6,717-5,407-7,551-5,126-6,017-7,256-7,577-8,001-4,805-4,307-4,288-6,805-3,600-3,124-5,347-5,000-4,300-4,679-3,327-5,347-3,847
  Share Based Compensation2.9%493479493513499535699514527556979433405415460408397382489318348
Cashflow From Investing100.0%--81.00-28.00-15.00----61.00-6.00-19.00----14.00-340-18.00-2.00-9.00-8.00-19.00-15.00
Cashflow From Financing-100.0%-4,465-4.0049.00141--11.00-12.00---24.00-74,7485,4841,76210,0125,291-52.0015,2815,521
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MBRX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues$ 0$ 0
Operating expenses:  
Research and development4,2525,687
General and administrative2,3932,637
Depreciation and amortization3230
Total operating expenses6,6778,354
Loss from operations(6,677)(8,354)
Other income:  
Gain from change in fair value of warrant liability1,45539
Other income, net118
Interest income, net241392
Net loss$ (4,970)$ (7,915)
Net loss per common share - basic and diluted (in dollars per share)$ (2.02)$ (4.13)
Weighted average common shares outstanding, basic and diluted (in shares)2,466,1741,916,665
Net loss$ (4,970)$ (7,915)
Other comprehensive loss:  
Foreign currency translation(9)(4)
Comprehensive loss$ (4,979)$ (7,919)

MBRX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 16,824$ 23,550
Prepaid expenses and other current assets2,1332,723
Total current assets18,95726,273
Furniture and equipment, net240272
Intangible assets11,14811,148
Operating lease right-of-use asset500524
Total assets30,84538,217
Liabilities, Current [Abstract]  
Accounts payable2,1042,498
Accrued expenses and other current liabilities3,3044,317
Total current liabilities5,4086,815
Operating lease liability - long-term, net of current portion450474
Warrant liability - long-term3,4004,855
Total liabilities9,25812,144
Commitments and contingencies (Note 7)
Stockholders' equity  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding00
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,311,536 and 2,227,516 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively233
Additional paid-in capital158,177157,653
Accumulated other comprehensive income (loss)(18)(9)
Accumulated deficit(136,574)(131,604)
Total stockholders’ equity21,58726,073
Total liabilities and stockholders’ equity$ 30,845$ 38,217
MBRX
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
 CEO
 WEBSITEmoleculin.com
 INDUSTRYBiotechnology
 EMPLOYEES15

Moleculin Biotech Inc Frequently Asked Questions


What is the ticker symbol for Moleculin Biotech Inc? What does MBRX stand for in stocks?

MBRX is the stock ticker symbol of Moleculin Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Moleculin Biotech Inc (MBRX)?

As of Fri Jul 12 2024, market cap of Moleculin Biotech Inc is 10.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBRX stock?

You can check MBRX's fair value in chart for subscribers.

What is the fair value of MBRX stock?

You can check MBRX's fair value in chart for subscribers. The fair value of Moleculin Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Moleculin Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MBRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Moleculin Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether MBRX is over valued or under valued. Whether Moleculin Biotech Inc is cheap or expensive depends on the assumptions which impact Moleculin Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBRX.